AdComm exodus: 2nd expert quits over FDA approval of Biogen's Aduhelm

AdComm exodus: 2nd expert quits over FDA approval of Biogen's Aduhelm

Source: 
Fierce Biotech
snippet: 

Another member of the FDA’s advisory committee on nervous system drugs has quit over the approval of Biogen’s Alzheimer’s disease product Aduhelm, Reuters reports. Mayo Clinic neurologist David Knopman, M.D., is the latest expert to leave the committee because of the FDA approval.